in this issue
Chemical Week Magazine :: Newsbriefs
Merck KGaA eyes pharma acquisitions, biosimilars
6:56 AM MDT | May 23, 2014
Merck KGaA plans to invest â‚¬100 million ($137 million) this year in biosimilars, a new business being developed by the companyâ€™s Merck Serono unit. Merck also is eyeing pharmaceutical acquisition opportunities, particularly in the United States, following its recent $2.6-billion acquisition of AZ Electronic Materials (CW, May 5/12, p. 21). â€śThe focus of the next two years will be on growth. We are aiming for organic and inorganic growth. The latter includes in-licensing agreements as well as acquisitions,â€ť Karl-Ludwig Kley, chairman of Merck KGaA, told...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee